IVA — Inventiva S.A.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1756594 ·
Last close
$3.22
Market Cap
$760.63M
52W High
$7.29
52W Low
$2.82
ADV30
2,746,920
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 251,210,000 166,128,000 192,208,000
Dec 2025 — — — — 249,511,000 99,312,000 278,033,000
Jun 2025 — — — — 178,955,000 122,076,000 187,863,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-69,467,000
Inventory
$0
Receivables
$10,413,000
ST Investments
$67,765,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
10

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,761,000
EBITDA
$-132,497,000
Free Cash Flow
$-200,711,632
Enterprise Value
$966,035,072
Total Cash
$99,839,000
Total Debt
$230,890,000
Shares Out
236,220,651
Trailing EPS
$-2.21
Book Value
$-0.17
ROE
—
ROA
-45.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 4,483,000 -132,883,000 -354,138,000 249,511,000 278,033,000 -28,522,000 -104,884,000
Dec 2024 9,198,000 -93,989,000 -184,212,000 118,967,000 225,613,000 -106,646,000 -85,928,000
Dec 2023 17,477,000 -102,665,000 -110,426,000 69,561,000 101,592,000 -32,031,000 -81,614,000
Dec 2022 12,179,000 -56,857,000 -54,274,000 116,004,000 70,528,000 45,476,000 -44,928,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.83

Max Pain — expiry 2027-01-15

max pain strike: $2.50 · spot: $3.39 · call oi: 28,928 · put oi: 1,488
Expected Move to 2027-01-15: ±$2.70 (79.65%) — implied range $0.69 – $6.09 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IVEVF Inventiva S.A. $751.18M $3.18 —
OBX Obsidian Therapeutics, Inc. $745.61M $12.07 —
APMD Apnimed, Inc. $741.03M $17.80 —
PAHC PHIBRO ANIMAL HEALTH CORP $737.01M $34.92 —
LXRX LEXICON PHARMACEUTICALS, INC. $792.52M $1.78 —

News headlines (Yahoo Finance, 1h cache)

Inventiva (IVA) vs. CRSP and MDGL: Can Lanifibranor’s Phase 3 Trial Unlock 62% Upside?
2026-10-28 13:13 · Yahoo
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
2026-10-10 14:35 · Yahoo
Inventiva (IVA): How Much Is One Make-or-Break Readout Really Worth?
2026-10-04 19:26 · Yahoo
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
2026-10-04 05:02 · Yahoo
Inventiva (IVA) Q2 2026 Earnings Call Transcript
2026-09-29 14:00 · Yahoo
Inventiva SA (IVEVF) (H1 2026) Earnings Call Highlights: Lanifibranor Nears Phase 3 Readout ...
2026-09-28 19:00 · Yahoo
Inventiva Q2 Earnings Call Highlights
2026-09-28 14:02 · Yahoo
Inventiva to Present Multiple Abstracts at Paris MASH 2026
2026-09-08 20:00 · Yahoo
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
2026-09-02 20:05 · Yahoo
Chris Benecchi Named Inventiva’s New Chief Operating Officer
2026-08-31 22:08 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.